Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

医学 拉米夫定 内科学 聚乙二醇干扰素 胃肠病学 HBeAg 联合疗法 乙型肝炎 人口 安慰剂 α-干扰素 α-干扰素 乙型肝炎病毒 免疫学 药理学 慢性肝炎 干扰素 乙型肝炎表面抗原 病毒 利巴韦林 病理 替代医学 环境卫生
作者
Harry L.A. Janssen,Monika van Zonneveld,Hakan Şentürk,Stefan Zeuzem,Ulus Salih Akarca,Yılmaz Çakaloğlu,Christopher Simon,Thomas M. K. So,Guido Gerken,Robert Auke de Man,Hubert G.M. Niesters,Pieter E. Zondervan,Bettina E. Hansen,Solko Walle Schalm
出处
期刊:The Lancet [Elsevier BV]
卷期号:365 (9454): 123-129 被引量:1241
标识
DOI:10.1016/s0140-6736(05)17701-0
摘要

Background Treatment of HBeAg-positive patients with chronic hepatitis B is not effective in most. A combination of immunomodulatory pegylated interferon alfa-2b and antiviral lamivudine might improve the rate of sustained response. Methods 307 HBeAg-positive patients with chronic hepatitis B were assigned combination therapy (100 μg/week pegylated interferon alfa-2b and 100 mg/day lamivudine) or monotherapy (100 μg/week pegylated interferon alfa-2b and placebo) for 52 weeks. During weeks 32–52 the pegylated interferon dose was 50 μg/week in both treatment groups. The analyses were based on the modified intention-to-treat population after exclusion of 24 patients from one centre withdrawn for misconduct, ten who lost HBeAg before the study start, and seven who received no study medication. All included patients were followed up for 26 weeks after treatment. Findings 49 (36%) of 136 patients assigned monotherapy and 46 (35%) of 130 assigned combination therapy had lost HBeAg at the end of follow-up (p=0·91). More of the combination-therapy than of the monotherapy group had cleared HBeAg at the end of treatment (57 [44%] vs 40 [29%]; p=0·01) but relapsed during follow-up. Patterns were similar when response was assessed by suppression of serum hepatitis B virus (HBV) DNA or change in concentrations of alanine aminotransferase. Response rates (HBeAg loss) varied by HBV genotype (p=0·01): A, 42 (47%) patients; B, ten (44%); C, 11 (28%); and D, 26 (25%). Interpretation Treatment with pegylated interferon alfa-2b is effective for HBeAg-positive chronic hepatitis B. Combination with lamivudine in the regimen used is not superior to monotherapy. HBV genotype is an important predictor of response to treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
不安的雅彤完成签到 ,获得积分10
1秒前
科研通AI6.3的应助被Dyying采纳,获得30
1秒前
1秒前
2秒前
3秒前
3秒前
fang完成签到 ,获得积分10
4秒前
jackson_WANG发布了新的文献求助10
4秒前
5秒前
Jude发布了新的文献求助10
5秒前
赵大大完成签到,获得积分10
5秒前
7秒前
7秒前
六六大顺发布了新的文献求助10
7秒前
8秒前
执着老九发布了新的文献求助10
8秒前
华仔的应助被边宇采纳,获得10
8秒前
NexusExplorer的应助被wyb采纳,获得10
11秒前
Brian完成签到,获得积分10
12秒前
赵云龙发布了新的文献求助10
12秒前
赵大大发布了新的文献求助10
12秒前
13秒前
13秒前
科研通AI6.3的应助被tlc_191026采纳,获得50
13秒前
fatcat完成签到,获得积分10
14秒前
香蕉寒珊发布了新的文献求助10
14秒前
小哲完成签到,获得积分10
14秒前
Brian发布了新的文献求助10
16秒前
边宇完成签到,获得积分10
17秒前
情怀的应助被牛战士采纳,获得10
18秒前
玉意发布了新的文献求助10
18秒前
19秒前
轻松的紫蓝完成签到,获得积分10
19秒前
852的应助被狂野雨梅采纳,获得30
20秒前
鲁酷发布了新的文献求助10
23秒前
24秒前
24秒前
舟渡完成签到,获得积分10
24秒前
25秒前
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183423
求助须知:如何正确求助?哪些是违规求助? 9572834
关于积分的说明 21827410
捐赠科研通 7780522
什么是DOI,文献DOI怎么找? 3434016
关于科研通互助平台的介绍 2558189
邀请新用户注册赠送积分活动 2480357